Anti-scalping pharmaceutical packaging film

1. A film for packaging a product comprising a pharmaceutical active agent, the film comprising:

a product-contacting sealing layer comprising at least 90 wt. % of an ethylene norbornene copolymer having a glass transition temperature in a range from 50° C. to 110° C.;

wherein the pharmaceutical active agent comprises one or more of fentanyl, nicotine, estradiol, clonidine, ethinyl estradiol, oxybutynin, buprenorphine, granisitron, methylphenidate, and scopolamine; and

wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the product-containing sealing layer of 0.5 or greater.

2. A film according to claim 1 , wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the polymeric sealing layer of 0.7 or greater.

3. A film according to claim 1 , wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the polymeric sealing layer of 1 or greater.

4. A film according to claim 1 , wherein the sealing layer consists essentially of ethylene norbornene copolymer.

5. A film according to any one of the preceding claims, wherein the product comprising the pharmaceutical active agent comprises a transdermal patch comprising the pharmaceutical active agent.

6. A packaged pharmaceutical product, comprising:

a film according to claim 1 , wherein the film has a total thickness of from about 1.0 to 10 mils, wherein the product-contacting sealing layer defines a sealed interior volume; and

the product comprising a pharmaceutical active agent disposed in the interior volume of the sealed package, wherein the pharmaceutical agent is in contact with the sealing layer.

7. A method for packaging a pharmaceutical product comprising a pharmaceutical active agent, the method comprising:

sealing the pharmaceutical product in an interior of a packaging film, wherein the film comprises a sealing layer comprising at least 90 wt. % of an ethylene norbornene copolymer having a glass transition temperature in a range from 65° C. to 110° C.,

wherein the pharmaceutical active agent comprises one or more of fentanyl, nicotine, estradiol, clonidine, ethinyl estradiol, buprenorphine, granisitron, and scopolamine;

wherein sealing the pharmaceutical product in the interior of the packaging film comprises placing the pharmaceutical agent in contact with the sealing layer, and

wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the polymeric sealing layer of 0.5 or greater.

8. A method according to claim 7 , wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the polymeric sealing layer of 1 or greater.

9. A method according to claim 7 , wherein the sealing layer comprises at least 95 wt. % ethylene norbornene copolymer.

10. A packaged pharmaceutical product comprising:

a drug resistant, flexible, multilayer packaging film comprising a drug contact layer having at least 90 wt. % of an ethylene norbornene copolymer having a glass transition temperature of from 55° C. to 110° C., wherein the film is formed into a flexible container;

a product comprising a pharmaceutical active agent, wherein the pharmaceutical active agent comprises one or more of fentanyl, nicotine, estradiol, clonidine, ethinyl estradiol, buprenorphine, granisitron, and scopolamine;

wherein the pharmaceutical active agent is in contact with the drug contact layer of the film and wherein the pharmaceutical active agent comprises a Hansen Solubility Parameter for the drug contacting layer of 0.7 or greater.

11. The packaged pharmaceutical product according to claim 10 , wherein the product comprising the pharmaceutical active agent comprises a transdermal patch comprising the pharmaceutical active agent and wherein the transdermal patch is a nicotine or fentanyl drug delivery patch.